Advertisement

Pharmacy World and Science

, Volume 27, Issue 2, pp 83–91 | Cite as

Choice of GPIIb/IIIa antagonist in percutaneous coronary intervention: how should economic criteria be factored in?

  • Claude Le PenEmail author
  • Hervé Lilliu
Article

Abstract

Objective: Three GPIIb/IIIa antagonists are available in the market. In France, as in many countries, their acquisition costs strongly differ. The objective of this study was to analyze how economic criteria–beyond the acquisition cost–should be factored in, when choosing a GPIIb/IIIa antagonist.

Method: Both clinical and economic papers on the use of GPIIb/IIIa antagonists in percutaneous coronary interventions published in peer-review journals from 1994 to 2002 were reviewed and analyzed.

Results: Cost differentials between products strongly vary from one ‘cost concept’ to another, i.e., acquisition cost, administration cost, hospital cost, net treatment cost. The comparison of efficacy is even more complicated, as most of the time only indirect comparisons are available, based on different clinical studies, with different durations and definitions of outcomes. Finally, cost-effectiveness ratios range from US$10695 per avoided event for eptifibatide (IMPACT II study) to US$74047 for tirofiban (RESTORE study).

Conclusion: The concept of cost, inevitably entering into the choice of a medicinal strategy, must be used with caution. The amplitude of the difference between products, and the product favored by the difference, vary according to the cost concept retained.

Keywords

Cost-effectiveness Costs GPIIb/IIIa antagonists Percutaneous coronary interventions Pharmacoeconomics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hillegass, WB, Newman, AR., Raco, DL. 2001Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromesEstimating the economic implications. Pharmacoeconomics.194155Google Scholar
  2. The EPIC Investigation use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. (1994) 330(14): 956–61Google Scholar
  3. The CAPTURE Study Randomised placebo-controlled trial of␣abciximab before and during coronary intervention in␣refractory unstable angina. Lancet 1997; 349(9063): 1429–35Google Scholar
  4. The EPILOG Investigators platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336(24): 1689–96Google Scholar
  5. Topol, EJ., Mark, DB, Lincoff, AM, Cohen, E, Burton, J, Kleiman N., N,  et al. 1999Outcomes at lyear and economic implications of platelet glycoprotein-IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trialEPISTENT investigators, Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet.354201924Google Scholar
  6. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998; 352(9122): 87–92Google Scholar
  7. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338(21): 1498–505Google Scholar
  8. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338(21): 1488–97Google Scholar
  9. The RESTORE Investigators Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96(5): 1445–53Google Scholar
  10. Topol, EJ, Moliterno, DJ, Herrmann, HC, Powers, ER, Grines, CL, Cohen, DJ,  et al. 2001Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularizationN Engl J Med.344188894CrossRefPubMedGoogle Scholar
  11. The TARGET investigators. Outcomes at 6months for direct comparison of tirfiban and abciximab during percutaneous coronary resvascularization with stent placement: the TARGET follow-up study. Lancet 2002; 360(9330): 355–60Google Scholar
  12. The PURSUIT trial investigators, Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339(7): 436–43Google Scholar
  13. IMPACT-II, Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. Lancet 1997; 349(9063): 1422–8Google Scholar
  14. O’Shea, JC, Hafley, GE, Greenberg, S, Hasselblad, V, Lorenz, TJ, Kitt, MM,  et al. 2001Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trialJAMA.285246873CrossRefPubMedGoogle Scholar
  15. Locher, F, Vainchtock, A, Baptiste, C, Pigeon, P. 2000Observatoire du coût des traitements par GPIIb/IIIa antagonist en cardiologieEt Eval Cardiovasc.733l58Google Scholar
  16. Lage, MJ, Barber, BL, McCollam, PL, Bala, M, Scherer, J. 2001Impact of abciximab versus tirofiban on hospital length of stay for PCI patientsCatheter Cardiovasc Interv.52298305CrossRefPubMedGoogle Scholar
  17. Collam, PL, Lage, MJ, Bala, M. 2001A comparison of total hospital costs for percutaneous coronary intervention patients receiving abciximab versus tirofibanCatheter Cardiovasc Interv.541527CrossRefPubMedGoogle Scholar
  18. Lucore, CL., Mishkel, GJ, Ligon, RW., Rocha-Singh, K. 1999Economic implications of coronary stenting with adjunctive IIb/IIIa receptor antagonists in a community hospitalJ Invasive Cardiol.1114C20CPubMedGoogle Scholar
  19. Narins, CR, Miller, DP, Califf, RM, Topol, EJ. 1999The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic ComplicationsJ Am ColI Cardiol.3364753CrossRefGoogle Scholar
  20. Cannon, CP. 1999Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarctionClin Cardiol.22IV30IV6PubMedGoogle Scholar
  21. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000; 356(9247): 2037–44Google Scholar
  22. Brown, DL, Fann, CS, Chang, CJ. 2001Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary interventionAm J Cardiol.8753741CrossRefPubMedGoogle Scholar
  23. Topol, EJ, Lincoff, AM, Kereiakes, DJ, Kleiman, NS, Cohen, EA, Ferguson JJ., etal. 2002Multi-year follow-up of abciximab therapy in three randomized, placebo- controlled trials of percutaneous coronary revascularizationAm J Med.11316CrossRefPubMedGoogle Scholar
  24. Bhatt, DL, Marso, SP, Lincoff, AM, Wolski, KE, Ellis, SG, Topol, EJ. 2000Abciximab reduces mortality in diabetics following percutaneous coronary interventionJ Am Coll Cardiol.359228CrossRefPubMedGoogle Scholar
  25. Brener, SJ, Barr, LA, Burchenal, JE, Katz, S, George, BS, Jones, AA,  et al. 1998Randomized, placebo controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) investigatorsCirculation.9873441PubMedGoogle Scholar
  26. Montalescot, G, Barragan, P, Wittenberg, O, Ecollan, P, Elhadad, S, Villain P., etal. 2001Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarctionN Engl J Med.3441895903CrossRefPubMedGoogle Scholar
  27. Stone, GW, Grines, CL, Cox, DA, Garcia, E, Tcheng, JE, Griffin JJ., etal. 2002Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarctionN Engl J Med.34695766CrossRefPubMedGoogle Scholar
  28. Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trail. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention. Am Heart J 2001; 141(3): 402–9Google Scholar
  29. Bell, DM. 1999Analysis of number needed to treat and cost of platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions and acute coronary syndromesPharmacotherapy.19108693CrossRefPubMedGoogle Scholar
  30. Dunn, CJ, Foster, RH, Abciximab.,  1999A pharmacoeconomic review of its use in percutaneous coronary revascularisationPharmacoeconomics .1671141PubMedGoogle Scholar
  31. Le Pen, C, Bonastre, J, Pinton, P. 1999Evaluation Médicoéconomique d’abciximabAnn Cardiol Angéiol.4817Google Scholar
  32. Kereiakes, DJ, Obenchain, RL, Barber, BL, Smith, A, McDonald, M, Broderick TM., etal. 2000Abciximab provides cost-effective survival advantage in high-volume interventional practiceAm Heart J.14060310CrossRefPubMedGoogle Scholar
  33. Mark, DB, Harrington, RA, Lincoff, AM, Califf, RM, Nelson, CL, Tsiatis AA., etal. 2000Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromesCirculation.10136671PubMedGoogle Scholar
  34. Brown, RE, Henderson, RA, Koster, D, Hutton, J, Simoons, ML. 2002Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial The Platelet IIa/IIb in unstable angina: receptor suppression using integrilin therapyEur Heart J.23508CrossRefPubMedGoogle Scholar
  35. McCcollam, PL, Foster, DA, Riesmeyer, JS. 2003Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary interventionAm J Health Syst Pharm.6012516PubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  1. 1.CLP-SantéParisFrance

Personalised recommendations